Under the collaboration, Topos will leverage Dalriada's expertise and infrastructure in protein mass spectrometry and chemoproteomics to support discovery efforts against intrinsically disordered and ...

Roche is supercharging drug discovery with a major AI expansion, deploying more than 3,500 NVIDIA Blackwell GPUs worldwide to transform how new medicines are developed. These systems reduce the need ...

French preclinical CRO NovAliX has found a new partner across the pond. Massachusetts-based manufacturer Bruker Corporation has announced a minority investment in the CRO. “This partnership with ...

The collaboration builds on Biophytis' ongoing partnership with LynxKite and aligns with Singapore’s research, innovation and enterprise (RIE) 2030 plan.

Roche now operates over 3,500 Nvidia Blackwell GPUs for AI-driven drug discovery, making it the pharma industry's largest ...

Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing ...

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies -- This partnership will generate revenue through: -- A computational ...

Figure 1. This figure depicts the four categories of protein druggability target screening tools discussed in this section, which include structure-based methods, sequence-based methods, machine ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...

Dalriada Drug Discovery (Dalriada), a partnered discovery organization supporting small-molecule programmes from hit identification through lead optimization, and Topos Bio (Topos), an AI-native ...